CNCCentene Corporation

$65.37+103% 1Y

$65.37

$31.7752 weeks$69.42

Is the price fair?

Good

Undemanding: modest expectations priced in and cheap against its own history.

2 good, 1 without data

What the price assumes~−20% a yearderived · Jun 30, 2026

Priced for a decline (~−20% a year). The price demands less than its three-year revenue growth of 11% a year, expectations look modest.

Vs its own P/E rangecheaper than 86% of its own historyderived

Cheap vs its own history: P/E 13.2 vs a 19.9 median over 37 quarters (−33% vs median).

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

FCF yieldtop 1% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

Today's price asks for −20% free cash flow growth a year; over the last three years Centene Corporation delivered 5.4%, less than the record.

0.15

Price / sales · no P/E: the last twelve months did not end in a profit

Free cash flow yield: 30%
Free cash flow yield · Healthcare Plans median 6.5%
Growth the price implies: −20%
Growth the price implies · The price pays for −20% free cash flow growth a year for a decade; the business has delivered +5.4% a year over the last three.
Price / book: 1.34
Price / book · today's price, trailing year to Jun 30, 2026

Details›

Price / booktoday's price, trailing year to Jun 30, 2026: 1.34
EV / EBIToperating margin −2.8%: the multiple describes the denominator: not meaningful
EV / salestoday's price, trailing year to Jun 30, 2026: 0.09
Free cash flow, trailing twelve months: $8.95B
Market capitalisation: $30.1B
3-year revenue growth: +11%
3-year free cash flow growth: +5.4%

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.

Ranks #191 of 446 by RyuScore